These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 4375276)

  • 21. [Comparative animal experiments concerning the distribution of 99mTc-pyrophosphate, 99mTc-diphosphonate and 85Sr (author's transl)].
    Büll U; Balser D; Frey KW
    Fortschr Geb Rontgenstr Nuklearmed; 1974 Apr; 120(4):481-8. PubMed ID: 4367024
    [No Abstract]   [Full Text] [Related]  

  • 22. Analysis of the relationship between 99mTc-Sn-polyphosphate and 99mTc-Sn-pyrophosphate.
    Bowen BM; Garnett ES
    J Nucl Med; 1974 Aug; 15(8):652-5. PubMed ID: 4366844
    [No Abstract]   [Full Text] [Related]  

  • 23. Technetium-99m-pyrophosphate: studies in vivo and in vitro.
    Kaye M; Silverton S; Rosenthall L
    J Nucl Med; 1975 Jan; 16(1):40-5. PubMed ID: 162947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical comparison of the kinetics of 99mTc pyrophosphate and 99mTc methylene diphosphonate (author's transl)].
    Casara D; Cimitan M; Zorat P; Calzavara F
    Radiol Med; 1979; 65(1-2):67-70. PubMed ID: 223200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 99m Tc-labelled chelates for nuclear medicine application. Radiopharmacy without knowledge of chemical structure?
    Nakken KF
    J Oslo City Hosp; 1984 Jun; 34(6):49-60. PubMed ID: 6088742
    [No Abstract]   [Full Text] [Related]  

  • 26. Technetium-99m-methylene diphosphonate--a superior agent for skeletal imaging: comparison with other technetium complexes.
    Subramanian G; McAfee JG; Blair RJ; Kallfelz FA; Thomas FD
    J Nucl Med; 1975 Aug; 16(8):744-55. PubMed ID: 170385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Investigations on the bone uptake of 99mTc-pyrophosphate, 99mTc-poly-phosphate and radio-strontium (author's transl)].
    Büll U; Frey KW
    Fortschr Geb Rontgenstr Nuklearmed; 1973 Nov; 119(5):569-77. PubMed ID: 4360989
    [No Abstract]   [Full Text] [Related]  

  • 28. Stannous pyrophosphate labeled with technetium-99m for skeletal scintigraphy.
    Hégésippe M; Beydon J; Bardy A; Pannecière C
    J Nucl Biol Med; 1973; 17(3):93-6. PubMed ID: 4355660
    [No Abstract]   [Full Text] [Related]  

  • 29. Time-dependent characteristics of Sn-complexes for preparing 99mTc-labelled radiopharmaceuticals and their bioavailabilities--a review.
    Noronha OP
    Nuklearmedizin; 1978 Jul; 17(3):110-25. PubMed ID: 704364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone uptake of 99mTc-phosphate via labeled plasma protein.
    Schümichen C; Seifritz R; Hoffmann G
    Nuklearmedizin; 1980 Aug; 19(4):174-7. PubMed ID: 6259628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of prior administration of Sn(II) complexes on in vivo distribution of 99mTc-pertechnetate.
    Khentigan A; Garrett M; Lum D; Winchell HS
    J Nucl Med; 1976 May; 17(5):380-4. PubMed ID: 1262943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The toxicity of Sn-pyrophosphate: clinical manifestations prior to acute LD50.
    Stevenson JS; Eckelman WC; Sobocinski PZ; Reba RC; Barron EL; Levin SG
    J Nucl Med; 1974 Apr; 15(4):252-6. PubMed ID: 4361926
    [No Abstract]   [Full Text] [Related]  

  • 33. [Complexes 99mTc-Sn-DTPA, 99mTc-Fe-ascorbic acid, and 99mTc-Sn-calcium-gluconogalactogluconate in the diagnosis of renal function and morphology (author's transl)].
    Licińska I; Graban W; Jakubowski W; Krasucki T; Lachnik E; Wiza J; Zulczyk W; Smoliński S; Zielińska B
    Pol Przegl Radiol Med Nukl; 1977; 41(1):57-61. PubMed ID: 859758
    [No Abstract]   [Full Text] [Related]  

  • 34. [Comparative quantitative scintigraphic studies with 99mTc pyrophosphate and 85Sr in pathologic bone transformation].
    Schmitt G; Strötges MW; Reinecke V
    Nucl Med (Stuttg); 1974 Aug; 13(2):103-12. PubMed ID: 4373696
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of preloading of stannous compounds on the distribution of 99mTc-pertechnetate.
    Greenberg DD; Som P; Meinken GE; Sacker DF; Atkins HL
    Nuklearmedizin; 1977 Feb; 16(1):26-9. PubMed ID: 191793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The use of 99mTc-pyrophosphate indices in the quantitative evaluation of rheumatoid arthritis activity].
    Jonderko G; Gabryel A; Gałaszek Z; Lewandowski J
    Z Rheumatol; 1980; 39(5-6):197-203. PubMed ID: 6251664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measurement of acute myocardial infarcts in dogs with 99mTc-stannous pyrophosphate scintigrams.
    Stokely EM; Buja LM; Lewis SE; Parkey RW; Bonte FJ; Harris RA; Willerson JT
    J Nucl Med; 1976 Jan; 17(1):1-5. PubMed ID: 172612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Proposals for the preparation and testing of radiopharmac critical agents. Proposal for the preparation and testing of 99m Tc-Sn pyrophosphate for bone scintigraphy].
    Charamza O
    Cesk Farm; 1974 Sep; 23(7):290. PubMed ID: 4373179
    [No Abstract]   [Full Text] [Related]  

  • 39. Bone kinetics of calcium-45 and pyrophosphate labeled with technetium-96: an autoradiographic evaluation.
    Guillemart A; Le Pape A; Galy G; Besnard JC
    J Nucl Med; 1980 May; 21(5):466-70. PubMed ID: 6246225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of localization of 99mTc-labeled pyrophosphate and tetracycline in infarcted myocardium.
    Dewanjee MK; Kahn PC
    J Nucl Med; 1976 Jul; 17(7):639-46. PubMed ID: 178842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.